NASDAQ:ODTOdonate Therapeutics Stock Price, Forecast & News

Odonate Therapeutics' stock was trading at $25.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ODT shares have increased by 56.6% and is now trading at $40.61.
View which stocks have been most impacted by COVID-19.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Odonate Therapeutics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell."
View analyst ratings for Odonate Therapeutics.

Odonate Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Odonate Therapeutics.

Odonate Therapeutics Inc (NASDAQ:ODT) released its earnings results on Thursday, July, 30th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.98) by $0.11.
View Odonate Therapeutics' earnings history.

1 equities research analysts have issued 12-month target prices for Odonate Therapeutics' shares. Their forecasts range from $26.00 to $26.00. On average, they anticipate Odonate Therapeutics' share price to reach $26.00 in the next year. This suggests that the stock has a possible downside of 36.0%.
View analysts' price targets for Odonate Therapeutics.

Press coverage about ODT stock has been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Odonate Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Odonate Therapeutics.

Odonate Therapeutics saw a increase in short interest in July. As of July 31st, there was short interest totaling 849,400 shares, an increase of 11.1% from the July 15th total of 764,300 shares. Based on an average daily trading volume, of 78,000 shares, the days-to-cover ratio is presently 10.9 days. Approximately 2.9% of the shares of the stock are short sold.
View Odonate Therapeutics' Short Interest.

Some companies that are related to Odonate Therapeutics include Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Evotec (EVTCY), FibroGen (FGEN), Legend Biotech (LEGN), HYPERA S A/S (HYPMY), Amicus Therapeutics (FOLD), Nektar Therapeutics (NKTR) and Arena Pharmaceuticals (ARNA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Odonate Therapeutics investors own include Exelixis (EXEL), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Bausch Health Companies (BHC), Crispr Therapeutics (CRSP), Fate Therapeutics (FATE), Mirati Therapeutics (MRTX), Viking Therapeutics (VKTX), AbbVie (ABBV) and Acorda Therapeutics (ACOR).

(ODT) raised $150 million in an initial public offering on Thursday, December 7th 2017. The company issued 5,900,000 shares at a price of $24.00-$27.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and Cowen was co-manager.

Odonate Therapeutics trades on the NASDAQ under the ticker symbol "ODT."

Odonate Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (0.17%), Assenagon Asset Management S.A. (0.16%), California Public Employees Retirement System (0.09%), Swiss National Bank (0.09%), Goldman Sachs Group Inc. (0.09%) and Bessemer Group Inc. (0.06%). Company insiders that own Odonate Therapeutics stock include Boxer Capital, Llc, Jeff L Vacirca and Kevin C Tang.
View institutional ownership trends for Odonate Therapeutics.

ODT stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, Chartwell Investment Partners LLC, Virtus ETF Advisers LLC, State of Wisconsin Investment Board, and UBS Group AG.
View insider buying and selling activity for Odonate Therapeutics.

ODT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Bessemer Group Inc., Goldman Sachs Group Inc., SG Americas Securities LLC, Bank of New York Mellon Corp, Russell Investments Group Ltd., New York State Common Retirement Fund, and American International Group Inc.. Company insiders that have bought Odonate Therapeutics stock in the last two years include Boxer Capital, Llc, Jeff L Vacirca, and Kevin C Tang.
View insider buying and selling activity for Odonate Therapeutics.

Shares of ODT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ODT stock can currently be purchased for approximately $40.61.

Odonate Therapeutics has a market capitalization of $1.30 billion. The company earns $-111,820,000.00 in net income (profit) each year or ($4.05) on an earnings per share basis. Odonate Therapeutics employs 117 workers across the globe.

The official website for Odonate Therapeutics is www.odonate.com.

Odonate Therapeutics' mailing address is 4747 EXECUTIVE DRIVE SUITE 510, SAN DIEGO CA, 92121. The company can be reached via phone at 858-731-8180 or via email at [email protected]